Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01323595 · ClinicalTrials.gov registry record · NA

Effectiveness of Celecoxib After Surgical Sperm Retrieval

A NA study, sponsored by Weill Medical College of Cornell University.

Terminated
Registry status
NA
Development phase
78
Enrollment target

NCT01323595: Clinical Trial NA study, sponsored by Weill Medical College of Cornell University.

NCT01323595 is a NA study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 78 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01323595, a NA study, was terminated before completion, sponsored by Weill Medical College of Cornell University.

TERMINATED
Registry status
NA
Development phase
78 participants
Enrollment target

Study Summary

While narcotic medication are commonly used for pain control near the time of surgery, there are significant side effects including constipation, nausea, risk of overdose leading to decreased breathing, and risk of addiction to narcotics. Our goal is to explore alternatives to narcotics for perioperative pain for patients undergoing sperm retrieval surgery. We have designed a prospective randomized clinical trial to evaluate how effective the anti-inflammatory medicine celecoxib(Celebrex©) is for pain control near the time of surgery. Celecoxib is known as a COX-2 inhibitor, a drug that belongs to the non-steroidal anti-inflammatory drug (NSAID) class. It is used to reduce swelling and to treat pain. Patients will be divided into two groups: the first group receives a celecoxib pill and the second group receives a sugar pill(placebo). Patients and doctors will be unaware of exactly which pills are given. The patient will complete questionnaires for pain level. By comparing the pain levels we can better understand whether celecoxib (Celebrex©) significantly decreases perioperative pain.

Primary Outcome

Patients will rate their pain for 7 days after surgery using an 11-point visual analog scale, ranging from 0 to 10, in which 0= no pain, 10=worst pain ever. Patients are asked to rate their pain up to four times a day during the post-operative period. Pain scores from each post-operative day each day will be averaged and reported as the pain score for that day.

Interventions

  • DRUG Celecoxib
  • DRUG Sugar Pill

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2011-01
Est. Completion 2013-03
Phase NA

Why NCT01323595 stopped before completion

NCT01323595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.

NCT01323595 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01323595 about?

NCT01323595 is a clinical study titled "Effectiveness of Celecoxib After Surgical Sperm Retrieval". While narcotic medication are commonly used for pain control near the time of surgery, there are significant side effects including constipation, nausea, risk of overdose leading to decreased breathing, and risk of addiction to narcotics. Our goal is to explore alternatives to narcotics for perioper...

What is the current status of trial NCT01323595?

This trial is currently terminated. It is a NA study. The enrollment target is 78 participants. The study started on 2011-01. Estimated completion is 2013-03.

What interventions are being tested in trial NCT01323595?

The interventions under investigation include: Celecoxib (DRUG), Sugar Pill (DRUG).

Who is sponsoring clinical trial NCT01323595?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01323595's enrollment target sits among peer trials

78 1060th of 2000 higher than 939 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02397668 · 78 participants · NA

    CorMatrix Cor TRICUSPID ECM Valve Replacement Study

  • NCT03321656 · 78 participants · Phase 2

    Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

  • NCT03687814 · 78 participants · NA

    Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation

  • NCT04018872 · 78 participants · Phase 2

    Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01323595, the US trial registry maintained by the National Library of Medicine. NCT01323595 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.